Latest News of SMED
Jim Cramer on TransMedics Group, Inc. (TMDX): 'I Don't Know How You Can Really Make A Lot Of Money In That Business, Frankly'
By Yahoo! Finance |
1 week ago
Jim Cramer analyzed how geopolitical concerns like the recent nuclear threat impact investor behavior, causing a flight-to-quality to safer investments like U.S. Treasury bonds. He noted that during s...
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
By Investor's Business Daily |
1 week ago
ResMed's Relative Strength Rating rose to 82, surpassing 80% of all stocks. The company's EPS and revenue growth have been strong, leading to a 34% surge in earnings last quarter....
ResMed Hits 80-Plus Relative Strength Rating Benchmark
By Investor's Business Daily |
1 week ago
Discover how Relative Strength (RS) Rating reveals market leadership, identifying stocks poised for big runs with an RS Rating above 80. Focus on factors like ResMed's financial performance and use IB...
-
Do You Believe in the Growth Potential of Insmed (INSM)?
By Yahoo! Finance | 4 weeks agoBaron Funds' "Baron Health Care Fund" Q3 2024 investor letter reveals a 5.81% gain compared to benchmarks. Highlighting Insmed Incorporated (NASDAQ:INSM), the biopharmaceutical company saw a one-month...
-
Decoding Insmed Inc (INSM): A Strategic SWOT Insight
By Yahoo! Finance | 4 weeks agoInsmed Inc faces potential financial challenges from market volatility and competition. Despite a strong balance sheet and robust product pipeline, operational losses persist due to high research and ...
-
How to play biotech stocks: Insmed and Wave Life Sciences
By Yahoo! Finance | 4 weeks agoEmerald Growth Fund's Stacey Sears suggests investing in small-cap biotech companies for growth opportunities in the healthcare sector. DNA and RNA editing advancements have led to breakthroughs in or...
-
TransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
By Yahoo! Finance | 1 month agoThe company forecasts revenue of $425 million to $445 million for the year, expecting growth of 76% to 84%. CEO Waleed Hassanein expressed confidence in the guidance, citing normalization in dynamics ...
-
Stocks Showing Market Leadership: ResMed Earns 92 RS Rating
By Investor's Business Daily | 1 month agoIBD's RS Rating tracks a stock's price performance against the market, with top growth stocks typically having a rating above 80. If a stock falls below its entry point by 7% after breaking out, it's ...
-
ResMed Inc (RMD) Q1 2025 Earnings Call Highlights: Strong Financial Performance Amid Global ...
By Yahoo! Finance | 1 month agoRest of World device growth is fueled by market performance and competition, with AirSense 11 contributing due to its higher price and demand. Mask sales in North America see double-digit growth from ...
-
TransMedics Faces Nine-Day Losing Streak as Valuation Concerns Loom Ahead of Earnings
By Yahoo! Finance | 1 month agoTransMedics Group, Inc. (NASDAQ:TMDX) has experienced a nine-day decline in its stock price, down 12% ahead of its Q3 2024 earnings report....
-
ResMed (NYSE:RMD) Eyes Growth with Board Expansion and Solid Earnings Despite Freight Cost Challenges
By Yahoo! Finance | 2 months agoResMed is experiencing growth with a 13.7% earnings increase and stable dividends, despite challenges like rising freight costs. The company's strengths, weaknesses, opportunities, and threats are ana...
-
Is Insmed Inc. (INSM) the Best Performing Stock in 2024?
By Yahoo! Finance | 2 months agoInsmed Inc. (NASDAQ:INSM) is a leading biopharmaceutical company focusing on rare lung diseases. Their innovative therapies show promise, positioning them as a top performer in 2024....
-
ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 74%
By Yahoo! Finance | 2 months agoInstitutional investors hold a 74% stake in ResMed Inc. (NYSE:RMD), potentially influencing stock price. While their ownership is significant, it's important to consider other factors like analyst sen...
-
Insmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential
By Yahoo! Finance | 2 months agoInsmed Inc. (NASDAQ:INSM) is a top mid-cap growth stock to buy, excelling in biopharmaceutical innovation with positive revenue growth and promising drug development....
-
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug
By Yahoo! Finance | 2 months agoThe Columbia Acorn Fund's Q2 2024 investor letter discussed the fund's -6.01% return compared to the benchmark's -4.22%, attributing underperformance to disappointing earnings....